2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2444

Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Abstract Number: 2445

Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis
Abstract Number: 2446

Infantile Hemangiomas in Infants Born to Women with Autoimmune Diseases
Abstract Number: 2447

Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
Abstract Number: 2448

Contraceptive Methods in Women with Rheumatoid Arthritis
Abstract Number: 2449

Infertility in Women with Rheumatoid Arthritis
Abstract Number: 2450

Do Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Have Reduced Fertility and Parity? a Systematic Review
Abstract Number: 2451

Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
Abstract Number: 2452

Reduced Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients
Abstract Number: 2453

The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
Abstract Number: 2454

Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine
Abstract Number: 2455

Transcriptome Profile of Cells Isolated from a CHB Heart Support an Exuberant Inflammatory ⁄Pro-Fibrotic Cascade
Abstract Number: 2456

Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Abstract Number: 2457

Role of Hydroxychloroquine in Improving Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease
Abstract Number: 2458

Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].